Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b studyTHE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic pain (DPNP) at two medical meetings: “New Promis ...

Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic ...

文章核心观点 - 公司宣布关于糖尿病周围神经病变性疼痛（DPNP）患者影响的研究数据将在会议上展示，希望提高医护人员对患者负担的认识，同时介绍了公司在研药物pilavapadin的情况 [1][3] 行业情况 - DPNP是糖尿病常见且易被忽视的慢性并发症，会导致手脚、腿部和手臂出现灼痛、麻木等症状，美国约有900万患者受影响，1型糖尿病患者中约30%、2型糖尿病患者中约50%受影响 [2] 公司研究 - 公司开展聚焦DPNP患者体验的研究，旨在让全球近1亿受影响人群“发声”，研究结果将于7月19日上午9:40 - 10:00以海报形式展示 [3] 公司药物 - pilavapadin（LX9211）是公司利用独特基因科学方法发现的小分子抑制剂，可抑制参与疼痛信号传导的神经递质再摄取和循环，不影响阿片类途径，临床前研究显示其能穿透中枢神经系统并减轻神经性疼痛模型中的疼痛行为 [4] - pilavapadin在2a期概念验证研究中达到主要终点，在缓解DPNP症状方面有显著且持续的益处，已获美国FDA快速通道认定 [5] 公司概况 - 公司是生物制药公司，通过Genome5000™计划研究近5000个基因，确定超100个有治疗潜力的蛋白质靶点，有一系列处于不同研发阶段的候选药物 [6]